Drug recall · January 29, 2020
Preferred Pharmaceuticals recall
Why: CGMP Deviations: Presence of NDMA impurity detected in product.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Preferred Pharmaceuticals, Inc, Ranitidine Tablets, 150 mg, a) 30 count bottles (NDC: 68788-7388-3), b) 60 count bottles (NDC: 68788-7388-6), c) 90 count bottles (NDC: 68788-7388-9), d) 100 count bottles (NDC: 68788-7388-1)
- Lots / codes
Lot #: All lots within expiry
- Quantity
- 221,710 tablets
- Company
- Preferred Pharmaceuticals, Inc, Anaheim, CA
- Distribution
- Distribution to physicians in the following states: AL, AZ, CA, FL, GA, IN, and SC
- Initiated
- January 7, 2020 · Voluntary: Firm initiated
- Classified
- January 20, 2020
- Reported
- January 29, 2020
- Ended
- December 14, 2023
- How notified
- Telephone
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Ranitidine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.